Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate in the study.
• People aged 18 or older at the time of joining the study.
• People whose cancer cannot be treated with surgery or other local treatments aimed at a cure.
• People who have had a biopsy confirming a specific type of liver cancer that has features of both hepatocellular carcinoma and cholangiocarcinoma (a mixed liver cancer).
• People who have not previously had any systemic (whole-body) treatment for their liver cancer.
• People who have at least one area of cancer that can be measured using a CT scan or MRI, according to standard measurement guidelines.
• People whose liver function and general physical condition fall within specific acceptable ranges, as assessed by standard medical scoring tools (confirm with trial site).
• People with a chronic hepatitis B (HBV) infection who have a very low level of the virus in their blood at screening, and who are already on antiviral medication following standard care guidelines.
• People who are expected to live for at least 12 weeks.
• People whose blood cell counts, liver enzyme levels, and kidney function all meet specific minimum requirements set by the trial (confirm with trial site for exact values).
• Female patients who could become pregnant and who have a negative pregnancy test within 7 days before starting the trial.
• People who are willing and able to follow all trial requirements, including attending scheduled appointments, following contraception guidelines, and completing follow-up visits.

Who may not be able to join:

• People who are on a waiting list for a liver transplant, or who have severe liver disease.
• People with a history of heart disease, or who have had a significant episode of gastrointestinal (gut) bleeding within the 4 weeks before starting the trial.
• People who have had a blood clot or blockage event — such as a stroke, mini-stroke (TIA), deep vein thrombosis, or pulmonary embolism — within the 6 months before the first dose (with one specific exception around portal vein clots — confirm with trial site).
• People who have previously received any systemic cancer treatment, hormone-based cancer therapy, or immunotherapy.
• People who have previously received a treatment called HAIC (hepatic arterial infusion chemotherapy).
• People who have or have had a second type of cancer, with the exception of certain treated skin cancers or early-stage cervical cancer.
• People with a weakened immune system, including those who are HIV-positive.
• People who have taken part in another clinical trial using an experimental treatment within the last 30 days before joining, or within a longer period depending on the previous trial medication (confirm with trial site).
• People who have previously received treatment within this same study.
• People with certain other medical conditions or health issues that, in the treating doctor's judgement, could interfere with the trial, including: a history of lung disease affecting the air sacs; having both hepatitis B and hepatitis C infections at the same time; known pancreatitis; active tuberculosis; any active infection requiring treatment; a history of organ or tissue transplant; a diagnosed immune deficiency or use of immune-suppressing medications within 7 days before starting; an active autoimmune disease requiring treatment in the past 3 months, or a history of severe autoimmune disease (some specific conditions are excepted — confirm with trial site); having received a live vaccine within 30 days before starting; or a history of cancer that has spread to the brain or central nervous system (some exceptions apply for people who have completed treatment and are stable — confirm with trial site).
• People taking medications known to interfere with the drugs used in this trial.
• People receiving any other active cancer treatment not specified by this trial's protocol.
• People who have received any other experimental treatment within 28 days of joining the study.
• People who have previously been treated with certain immune checkpoint or T-cell targeting therapies, including specific types of antibody treatments (confirm with trial site for the full list).
• People who are pregnant, breastfeeding, or people of reproductive potential who are not using an effective method of contraception as defined by the trial (acceptable methods include implants, injectable contraceptives, combined oral contraceptives, hormonal intrauterine devices, sexual abstinence, or a partner's vasectomy). Female patients of childbearing potential must also have a negative pregnancy blood test at screening.
• People with a significant history of not following medical instructions, or who are unable to provide reliable informed consent.

Important: Always verify eligibility with the trial site directly before applying.